QPPV.COM

Computerised System Validation Plan

Learn how to develop a Computerised System Validation Plan that defines validation strategy, responsibilities, deliverables and lifecycle activities for regulated pharmacovigilance systems.

Computerised System Validation Plan

Introduction

Successful Computerised System Validation begins long before the first validation test is executed. Organisations must first determine how validation will be performed, who will perform it, what evidence will be generated and how confidence in the validated state will be maintained throughout the system lifecycle.

The Computerised System Validation Plan (CSV Plan) provides this framework.

Rather than describing the technical implementation of a computerised system, the Validation Plan defines the overall validation strategy. It explains the intended use of the system, the scope of validation, the application of quality risk management, validation deliverables, roles and responsibilities, testing strategy and lifecycle activities that will be used to demonstrate that the system is fit for its intended use.

For pharmacovigilance systems, where computerised applications support Individual Case Safety Report processing, electronic regulatory reporting, signal management, aggregate reporting and other regulated activities, a well-developed Validation Plan provides the governance structure that guides all subsequent validation work.

Modern guidance, including ISPE GAMP 5 Second Edition and the FDA Computer Software Assurance (CSA) initiative, encourages organisations to develop validation strategies that are proportionate to risk and focused on generating meaningful objective evidence rather than unnecessary documentation.

Learning Objectives

After reading this article, you should be able to:

Why a Computerised System Validation Plan Exists

Computerised System Validation consists of numerous interrelated activities, including requirements definition, risk assessment, system design, configuration, validation testing, change control and lifecycle management. Without a clearly defined strategy, these activities may become inconsistent, incomplete or unnecessarily complex.

The Computerised System Validation Plan provides the governance framework that coordinates these activities into a structured validation programme.

Rather than describing how the system functions, the Validation Plan explains how the organisation will demonstrate that the system is fit for its intended use.

It establishes the principles, responsibilities and validation strategy that guide every subsequent validation activity.

Providing a Validation Strategy

One of the principal purposes of the Validation Plan is to define the overall validation strategy before validation work begins.

The plan should explain:

By documenting these decisions early, organisations ensure that validation activities remain consistent throughout the project.

Establishing Governance

Validation requires participation from multiple disciplines, including business users, pharmacovigilance personnel, information technology, quality assurance and system suppliers.

The Validation Plan establishes governance by defining:

Clearly defined governance reduces uncertainty and promotes consistent execution of validation activities.

Supporting Risk-Based Validation

Modern Computerised System Validation is based upon quality risk management.

Accordingly, the Validation Plan should explain how risks will influence:

Documenting this approach ensures that validation effort remains proportionate to the significance of the regulated activities supported by the system.

Defining Validation Deliverables

The Validation Plan identifies the documentation that will be produced during the validation lifecycle.

Typical deliverables include:

Identifying these deliverables at the outset improves planning and supports project governance.

Supporting Lifecycle Management

The purpose of the Validation Plan extends beyond initial implementation.

The plan should also describe how the organisation intends to maintain confidence in the validated state throughout:

Validation should therefore be viewed as a continuous lifecycle activity rather than a single implementation project.

Supporting Inspection Readiness

Inspectors frequently review the Validation Plan to understand the organisation's validation strategy before examining individual validation documents.

A well-written Validation Plan enables inspectors to understand:

This provides important context for the remainder of the validation programme.

A Governance Document Rather Than a Technical Specification

The Validation Plan should not describe detailed system functionality.

Instead, it explains how validation will be organised, governed and documented.

Technical implementation belongs within specifications and validation protocols.

The Validation Plan remains focused on strategy, governance and lifecycle management.

Scientific Foundation

A Computerised System Validation Plan establishes the strategy, governance and lifecycle framework through which an organisation demonstrates that a pharmacovigilance computerised system is fit for its intended use. By defining responsibilities, validation activities, quality risk management principles and lifecycle controls before implementation begins, the Validation Plan provides the foundation for a consistent, scientifically justified and inspection-ready validation programme.

Fundamental Principles of a Computerised System Validation Plan

An effective Computerised System Validation Plan is founded upon a number of principles that ensure validation activities remain scientifically justified, proportionate to risk and capable of demonstrating that the computerised system is fit for its intended use.

These principles apply regardless of whether the system is developed internally, implemented as Commercial Off-the-Shelf software or delivered as a Software-as-a-Service solution.

Collectively, they provide the foundation for a consistent and inspection-ready validation programme.

Intended Use Drives Validation

The intended use of the computerised system should determine every aspect of the validation strategy.

Before defining validation activities, organisations should clearly understand:

Validation activities should then be designed to demonstrate that the implemented system supports this intended use consistently and reliably.

Validation Is a Lifecycle Activity

Validation should not be viewed as a project completed immediately before production deployment.

Instead, it should continue throughout the operational life of the computerised system.

The Validation Plan should therefore describe activities supporting:

Maintaining this lifecycle perspective helps preserve the validated state over time.

Validation Should Be Risk Based

Modern validation programmes apply quality risk management to determine where validation effort should be directed.

The Validation Plan should explain how risk will influence:

Critical pharmacovigilance functions should receive proportionately greater validation attention than lower-risk administrative activities.

Objective Evidence Is Essential

Validation conclusions should always be supported by objective evidence.

Examples include:

The Validation Plan should describe how this evidence will be generated, reviewed, approved and retained throughout the system lifecycle.

Validation Should Be Proportionate

Validation activities should be appropriate for the complexity and regulatory significance of the computerised system.

Factors influencing proportionality include:

Applying the same validation effort to every system rarely represents an efficient use of resources.

Governance Supports Consistency

Successful validation depends upon effective governance.

The Validation Plan should define:

Clear governance promotes consistency and accountability throughout the validation lifecycle.

Documentation Should Support Understanding

Validation documentation should communicate how confidence in the validated state has been established.

Documents should therefore be:

Documentation should support scientific reasoning rather than merely satisfy administrative requirements.

Maintaining the Validated State

Production deployment represents the beginning rather than the end of validation.

The Validation Plan should describe how confidence in the validated state will be maintained through:

These activities demonstrate that the computerised system remains suitable for its intended use despite ongoing operational and technical change.

Continuous Improvement

Validation programmes should evolve in response to experience, regulatory developments and technological advances.

The Validation Plan should therefore support periodic evaluation of:

Continuous improvement strengthens both compliance and operational efficiency throughout the system lifecycle.

Scientific Foundation

A Computerised System Validation Plan is founded upon lifecycle thinking, quality risk management, objective evidence and effective governance. By applying these principles consistently, organisations establish a validation programme that provides meaningful assurance that pharmacovigilance computerised systems remain fit for their intended use throughout their operational lifecycle.

Scope of the Computerised System Validation Plan

The Computerised System Validation Plan should clearly define the systems, activities and lifecycle processes that fall within its scope. Establishing these boundaries ensures that validation activities remain focused, proportionate and aligned with the intended use of the computerised system.

A clearly defined scope also enables reviewers, project teams and regulatory inspectors to understand precisely which components are governed by the Validation Plan and which activities are managed through other organisational procedures.

Defining the System Boundary

The Validation Plan should identify the boundaries of the computerised system.

This should include:

Defining these boundaries establishes the foundation for risk assessment, validation planning and lifecycle management.

Business Processes Within Scope

The Validation Plan should identify the regulated business processes supported by the computerised system.

For pharmacovigilance systems these may include:

Identifying supported business processes ensures that validation activities remain aligned with operational use.

Interfaces Within Scope

Most pharmacovigilance systems exchange information with other computerised systems.

The Validation Plan should identify interfaces such as:

Each interface should be considered during risk assessment and validation planning because failures may affect regulated activities beyond the primary application.

Infrastructure and Platform Components

Depending upon the implementation model, infrastructure may form part of the validation scope.

Examples include:

The Validation Plan should explain which infrastructure components require local qualification and which are supported through supplier evidence.

Commercial Off-the-Shelf and SaaS Solutions

For Commercial Off-the-Shelf (COTS) and Software-as-a-Service (SaaS) solutions, the Validation Plan should distinguish between supplier-managed activities and those performed by the regulated organisation.

Examples of supplier responsibilities include:

Examples of organisational responsibilities include:

Clearly defining these responsibilities supports effective governance and supplier oversight.

Activities Outside the Scope

A well-written Validation Plan should also identify activities that are not governed by the document.

Examples may include:

Defining exclusions prevents duplication of governance activities and reduces ambiguity during inspections.

Global and Local Implementations

Many Marketing Authorisation Holders operate global pharmacovigilance systems while maintaining local organisational processes.

The Validation Plan should clarify:

This distinction assists multinational organisations in maintaining consistent validation practices while accommodating regional operational differences.

Scope Should Reflect Intended Use

The scope of the Validation Plan should always be determined by the intended use of the computerised system.

Activities that influence patient safety, data integrity or regulatory compliance should be included within the validation strategy.

Conversely, activities that do not affect the intended use or validated state should generally be managed through other organisational governance processes.

Maintaining this focus helps ensure that validation effort remains proportionate and scientifically justified.

Scientific Foundation

The scope of a Computerised System Validation Plan defines the boundaries within which validation activities are planned, executed and maintained. By clearly identifying the systems, business processes, interfaces, infrastructure and organisational responsibilities governed by the plan, organisations establish a structured framework for risk-based validation and lifecycle management of pharmacovigilance computerised systems.

Intended Use of the Computerised System

The intended use of a computerised system defines the purpose for which the system is implemented within the organisation. It describes the regulated business activities the system is expected to support, the users who will operate the system and the operational environment in which it will function.

The intended use provides the foundation for every subsequent validation activity.

Risk assessments, User Requirements Specifications, system specifications, validation testing, acceptance criteria, change control and periodic review should all demonstrate that the computerised system remains fit for its intended use.

Without a clearly defined intended use, it becomes difficult to determine the appropriate scope or depth of validation.

Why Intended Use Is Important

Modern Computerised System Validation is based upon demonstrating that a system is fit for its intended use rather than proving that every software function operates correctly.

Accordingly, validation should answer a fundamental question:

Can this computerised system consistently support the regulated business activities for which it has been implemented?

The intended use therefore establishes the benchmark against which validation success is evaluated.

Intended Use Determines Validation Scope

The intended use directly influences the scope of validation.

It helps determine:

Validation effort should therefore remain proportionate to the intended use rather than the total number of software functions available.

Intended Use Determines Risk Assessment

Quality risk management begins with understanding how the system will be used.

The intended use enables organisations to identify risks that could affect:

These identified risks subsequently influence validation strategy, testing priorities and lifecycle management activities.

Intended Use Determines Requirements

Business and User Requirements should describe the capabilities necessary to support the intended use.

Requirements should not simply document available software functionality.

Instead, they should explain what the organisation requires to perform regulated pharmacovigilance activities safely, consistently and in compliance with applicable regulatory requirements.

This relationship ensures that validation remains focused on business objectives rather than software features.

Intended Use Determines Validation Testing

Validation testing should demonstrate that the implemented system supports its intended operational purpose.

Testing should therefore evaluate representative business processes rather than isolated software functions.

For pharmacovigilance systems this commonly includes:

The selected validation activities should generate objective evidence that these regulated processes operate successfully under representative conditions.

Characteristics of a Good Intended Use Statement

An effective intended use statement should be:

It should describe what the system is intended to achieve rather than how the software performs those activities.

Pharmacovigilance Example

An intended use statement for a pharmacovigilance safety database might be:

"The system is intended to support the collection, processing, medical assessment, regulatory reporting and long-term management of Individual Case Safety Reports while maintaining data integrity, audit trails and compliance with applicable pharmacovigilance regulatory requirements."

This statement defines the purpose of the system without prescribing its technical implementation.

Validation activities can then demonstrate that this intended use has been achieved.

Common Mistakes

Common weaknesses include:

These weaknesses may result in inappropriate validation scope, incomplete risk assessment and poorly targeted validation testing.

Intended Use Throughout the Lifecycle

The intended use should remain stable throughout the operational lifecycle unless formally modified through change control.

Whenever significant changes occur, organisations should evaluate whether:

Maintaining alignment between intended use and system operation is essential for preserving the validated state.

Intended Use Guides Every Validation Decision

Experienced validation professionals recognise that the intended use is more than an introductory statement within the Validation Plan.

It is the organising principle that connects:

Every significant validation decision should ultimately support confidence that the computerised system remains fit for this intended use.

Scientific Foundation

The intended use defines the regulated purpose of a computerised system and serves as the foundation for Computerised System Validation. By aligning risk assessments, requirements, validation activities and lifecycle management with the intended use, organisations generate objective evidence that pharmacovigilance systems remain fit for their intended purpose throughout their operational lifecycle.

Validation Strategy

The Validation Strategy describes the overall approach the organisation will use to demonstrate that the computerised system is fit for its intended use throughout its operational lifecycle.

Rather than listing individual validation activities, the strategy explains the principles that determine how validation will be planned, executed, reviewed and maintained.

An effective Validation Strategy ensures that validation activities remain scientifically justified, proportionate to risk and aligned with applicable regulatory expectations.

A Lifecycle-Based Strategy

Validation should be planned as a lifecycle activity rather than a single implementation project.

The Validation Strategy should therefore describe activities covering:

Planning validation across the complete lifecycle provides confidence that the validated state will be maintained beyond initial implementation.

Applying Quality Risk Management

The Validation Strategy should explain how quality risk management will influence validation activities.

Risk assessments should determine:

Functions presenting greater risks to patient safety, data integrity or regulatory compliance should receive proportionately greater validation attention.

Defining the Validation Approach

The Validation Strategy should identify the validation activities appropriate for the computerised system.

These commonly include:

The selected activities should reflect the intended use, implementation model and complexity of the system.

Leveraging Supplier Evidence

Modern pharmacovigilance systems are frequently implemented using Commercial Off-the-Shelf software or Software-as-a-Service platforms.

The Validation Strategy should explain how supplier documentation will be evaluated and incorporated into the validation programme.

Examples include:

Supplier evidence should be used where appropriate while ensuring that organisation-specific configuration and business processes remain independently validated.

Generating Objective Evidence

Validation conclusions should always be supported by objective evidence.

The Validation Strategy should identify the forms of evidence expected throughout the validation lifecycle.

Examples include:

Evidence should demonstrate not only that validation activities were performed but also that they support confidence in the validated state.

Managing Validation Deviations

Unexpected outcomes should be anticipated within every validation programme.

The Validation Strategy should describe how deviations will be:

Managing deviations consistently strengthens confidence in both the validation programme and the validated system.

Maintaining the Validated State

Validation does not conclude when the system enters production.

The Validation Strategy should explain how confidence in the validated state will be maintained through:

These activities ensure that validation remains current despite technical and organisational change.

Alignment with Modern Validation Guidance

Modern validation guidance encourages organisations to generate meaningful assurance rather than excessive documentation.

Accordingly, the Validation Strategy should emphasise:

This approach aligns with the principles described in ISPE GAMP 5 Second Edition and the FDA Computer Software Assurance initiative.

Characteristics of an Effective Validation Strategy

An effective Validation Strategy is:

These characteristics enable organisations to demonstrate that validation activities remain both scientifically justified and operationally effective.

Scientific Foundation

A Computerised System Validation Strategy defines how an organisation will establish and maintain confidence that a pharmacovigilance computerised system is fit for its intended use. By integrating lifecycle management, quality risk management, objective evidence, supplier oversight and ongoing governance, the strategy provides the framework for a consistent, efficient and inspection-ready validation programme.

Roles and Responsibilities

Successful Computerised System Validation depends upon clearly defined roles and responsibilities. Validation cannot be performed effectively by a single department because it requires contributions from business users, pharmacovigilance personnel, information technology, quality assurance, suppliers and senior management.

The Computerised System Validation Plan should define who is responsible for planning, executing, reviewing, approving and maintaining validation activities throughout the lifecycle of the computerised system.

Clearly documented responsibilities promote accountability, reduce ambiguity and strengthen governance.

Business Process Owner

The Business Process Owner is responsible for ensuring that the computerised system supports the intended business processes.

Responsibilities commonly include:

The Business Process Owner provides assurance that validation activities reflect operational needs rather than purely technical objectives.

System Owner

The System Owner has overall responsibility for the validated state of the computerised system throughout its operational lifecycle.

Typical responsibilities include:

The System Owner remains accountable for ensuring that the system continues to satisfy its intended use following production deployment.

Pharmacovigilance and the QPPV

For pharmacovigilance systems, the Qualified Person Responsible for Pharmacovigilance (QPPV) is not normally responsible for executing validation activities.

However, the QPPV should have confidence that computerised systems supporting regulated pharmacovigilance activities remain suitable for their intended use.

Depending upon organisational governance, responsibilities may include:

The precise responsibilities of the QPPV should be defined within the organisation's pharmacovigilance system.

Validation Lead

The Validation Lead coordinates the execution of the validation programme.

Responsibilities commonly include:

The Validation Lead ensures that validation activities are performed consistently and in accordance with approved procedures.

Quality Assurance

Quality Assurance provides independent oversight of the validation programme.

Responsibilities typically include:

Independent quality oversight strengthens confidence in the integrity of the validation programme.

Information Technology

Information Technology supports the technical implementation and ongoing operation of the computerised system.

Responsibilities may include:

Where infrastructure is managed by a cloud provider or software supplier, local Information Technology responsibilities should be clearly defined.

Suppliers and Service Providers

Commercial software suppliers and outsourced service providers frequently contribute to validation activities.

Examples include:

The Validation Plan should clearly distinguish supplier responsibilities from those retained by the regulated organisation.

Ultimate responsibility for demonstrating fitness for intended use remains with the Marketing Authorisation Holder.

End Users

End users contribute practical knowledge regarding routine system operation.

Responsibilities commonly include:

User participation helps ensure that validated functionality reflects actual operational practice.

Senior Management

Senior management provides organisational support and resources for validation.

Responsibilities may include:

Management commitment contributes to the long-term effectiveness of the validation programme.

Responsibility and Accountability

Although responsibilities may be delegated, accountability for maintaining the validated state should remain clearly defined.

The Validation Plan should identify:

Many organisations support this using responsibility assignment matrices, such as RACI models, provided that accountability remains clear and appropriately documented.

Governance Throughout the Lifecycle

Roles and responsibilities should continue throughout:

Maintaining clearly defined responsibilities throughout the lifecycle strengthens governance and helps preserve confidence in the validated state.

Scientific Foundation

Effective Computerised System Validation depends upon clearly defined responsibilities supported by appropriate governance and independent oversight. By assigning ownership for validation planning, execution, review and lifecycle management, organisations establish accountability for maintaining pharmacovigilance computerised systems in a controlled and validated state throughout their operational lifecycle.

Validation Deliverables

The Computerised System Validation Plan should identify the documentation that will be produced throughout the validation lifecycle. Collectively, these documents provide objective evidence that the computerised system has been planned, implemented, validated and maintained in accordance with its intended use.

Each deliverable has a distinct purpose within the validation programme. Together, they demonstrate that validation activities have been performed systematically, are supported by objective evidence and remain appropriate throughout the operational lifecycle of the system.

Validation Plan

The Validation Plan is the governing document for the validation programme.

It establishes:

The Validation Plan should be approved before detailed validation activities begin.

Risk Assessment

The Risk Assessment identifies hazards that could affect:

It provides the scientific justification for determining validation scope, testing priorities and lifecycle controls.

Risk assessments should be reviewed whenever significant changes occur.

User Requirements Specification

The User Requirements Specification (URS) defines what the business requires the computerised system to achieve.

The URS should describe:

Validation testing should ultimately demonstrate that these requirements have been satisfied.

Functional and Configuration Specifications

Functional Specifications describe how approved requirements will be achieved.

Where Commercial Off-the-Shelf software is implemented, Configuration Specifications frequently replace detailed Design Specifications by documenting how supplier functionality has been configured to satisfy organisational requirements.

These documents provide the technical foundation for validation testing.

Traceability Matrix

The Traceability Matrix demonstrates relationships between:

It provides confidence that validation remains complete throughout the lifecycle of the system.

Validation Protocols

Validation protocols describe how objective evidence will be generated.

Depending upon the validation strategy, protocols may include:

Each protocol should define:

Validation Evidence

Execution of validation protocols produces objective evidence supporting validation conclusions.

Examples include:

Evidence should comply with Good Documentation Practices and remain attributable, complete and readily retrievable.

Validation Report

The Validation Report summarises the outcome of the validation programme.

Typical contents include:

The report provides formal documented justification that the computerised system is fit for its intended use.

Lifecycle Documentation

Validation documentation continues after production deployment.

Examples include:

These records demonstrate that confidence in the validated state has been maintained throughout the operational lifecycle.

Relationships Between Deliverables

Validation deliverables should not be viewed as independent documents.

Instead, they form an integrated validation framework.

A typical sequence is:

Business Need

↓

Validation Plan

↓

Risk Assessment

↓

User Requirements Specification

↓

Functional or Configuration Specification

↓

Traceability Matrix

↓

Validation Protocols

↓

Validation Evidence

↓

Validation Report

↓

Production Release

↓

Change Control

↓

Periodic Review

↓

System Retirement

Each deliverable builds upon the previous documentation while generating additional objective evidence supporting confidence in the validated system.

Deliverables Support Inspection Readiness

Regulatory inspectors frequently review validation documentation collectively rather than individually.

The complete set of validation deliverables enables organisations to demonstrate:

Collectively, these documents provide comprehensive evidence that the pharmacovigilance computerised system remains fit for its intended use.

Scientific Foundation

Validation deliverables form an integrated body of objective evidence supporting the validated state of a pharmacovigilance computerised system. Each document contributes a specific element of planning, implementation, verification or lifecycle management, while collectively demonstrating that the system has been validated systematically and continues to satisfy its intended use throughout its operational lifecycle.

Risk-Based Validation Planning

Modern Computerised System Validation is founded upon the principles of quality risk management. Rather than applying identical validation activities to every system function, organisations should direct validation effort towards those areas presenting the greatest potential impact on patient safety, product quality, data integrity and regulatory compliance.

Accordingly, the Validation Plan should describe how quality risk management will be applied throughout the validation lifecycle.

This approach aligns with the principles described in ICH Q9 Quality Risk Management, ISPE GAMP 5 Second Edition and the FDA Computer Software Assurance initiative.

The Purpose of Risk-Based Validation

The objective of risk-based validation is not to reduce validation activities indiscriminately.

Instead, it seeks to ensure that validation resources are directed towards functions where objective evidence provides the greatest assurance.

This approach enables organisations to:

Validation effort should therefore reflect risk rather than documentation tradition.

Identifying Critical Functions

The Validation Plan should describe how critical system functions will be identified.

For pharmacovigilance systems, these commonly include:

These functions generally require greater validation attention because failures may have direct regulatory or patient safety consequences.

Assessing Risk

Quality risk management should consider both the significance of the regulated activity and the potential consequences of failure.

Factors commonly evaluated include:

The Validation Plan should describe the methodology used to perform these assessments and how the resulting conclusions influence validation activities.

Determining Validation Effort

Following risk assessment, organisations should determine the appropriate validation approach for each significant function.

Higher-risk functions may require:

Lower-risk functions may require proportionately less formal validation while still demonstrating that they support the intended use of the system.

This proportional approach improves efficiency without reducing regulatory assurance.

Applying Risk Throughout the Lifecycle

Risk assessment should not be performed only during initial implementation.

The Validation Plan should explain how risk assessments will be reviewed following:

This ensures that validation activities remain aligned with current rather than historical risks.

Supplier Evidence and Risk

Supplier documentation should also be evaluated using quality risk management principles.

Organisations should determine:

This enables efficient use of supplier documentation while maintaining responsibility for demonstrating that the implemented system remains fit for its intended use.

Risk-Based Regression Testing

The Validation Plan should describe how quality risk management will influence regression testing following approved changes.

Rather than repeating every historical validation activity, organisations should identify:

Regression testing can then be focused on functionality genuinely affected by the proposed change.

Risk-Based Inspection Readiness

Risk-based validation also supports inspection readiness.

Inspectors increasingly expect organisations to explain why particular validation activities were selected.

The Validation Plan should therefore demonstrate that validation decisions are supported by documented risk assessments rather than historical practice or administrative convenience.

A clearly documented risk-based rationale strengthens confidence that validation activities remain proportionate, scientifically justified and aligned with current regulatory expectations.

Risk Management Supports Continuous Improvement

Risk assessments should evolve as knowledge of the system increases.

Validation experience, operational incidents, audit observations, supplier releases and regulatory developments may all influence future validation priorities.

The Validation Plan should therefore encourage periodic review of risk assessments to ensure that validation effort continues to focus on areas presenting the greatest potential impact.

This approach promotes continual improvement while maintaining confidence in the validated state.

Scientific Foundation

Risk-based validation planning applies the principles of quality risk management to determine the scope, depth and ongoing maintenance of Computerised System Validation. By directing validation activities towards functions presenting the greatest potential impact on patient safety, data integrity and regulatory compliance, organisations generate meaningful objective evidence while maintaining an efficient and scientifically justified validation programme.

Supplier Qualification and Supplier Involvement

Modern pharmacovigilance computerised systems are commonly implemented using Commercial Off-the-Shelf (COTS) applications or Software-as-a-Service (SaaS) platforms supplied by specialist vendors. Consequently, Computerised System Validation frequently depends upon collaboration between the regulated organisation and one or more external suppliers.

The Validation Plan should describe how suppliers will be assessed, how supplier documentation will be evaluated and how supplier activities will be incorporated into the overall validation programme.

Although suppliers perform many technical activities, responsibility for demonstrating that the implemented system is fit for its intended use remains with the Marketing Authorisation Holder.

The Importance of Supplier Qualification

Supplier qualification provides confidence that the organisation is selecting a supplier capable of delivering products and services appropriate for use within a regulated pharmacovigilance environment.

Supplier qualification should be proportionate to the significance of the computerised system and may consider:

The Validation Plan should describe how supplier suitability will be assessed before implementation begins.

Defining Supplier Responsibilities

The Validation Plan should distinguish activities performed by the supplier from those retained by the regulated organisation.

Supplier responsibilities may include:

Clearly defining these responsibilities reduces ambiguity throughout the validation lifecycle.

Organisational Responsibilities

Regardless of the implementation model, the regulated organisation remains responsible for ensuring that the implemented solution supports regulated pharmacovigilance activities.

Responsibilities commonly include:

These responsibilities cannot be delegated entirely to the software supplier.

Leveraging Supplier Documentation

Supplier documentation may contribute valuable objective evidence within the validation programme.

Examples include:

The Validation Plan should explain how supplier documentation will be reviewed, evaluated and incorporated into local validation activities.

Supplier evidence should complement, rather than replace, organisation-specific validation.

Supplier Audits and Assessments

For systems supporting regulated pharmacovigilance activities, organisations may perform supplier assessments or audits where appropriate.

These activities may evaluate:

Findings from supplier assessments should influence validation planning and ongoing supplier oversight.

Cloud and Software-as-a-Service Providers

Cloud-hosted and Software-as-a-Service solutions require particular attention because responsibility is shared between the supplier and the regulated organisation.

The Validation Plan should identify responsibilities relating to:

Documenting these responsibilities supports effective governance throughout the operational lifecycle.

Supplier Releases and Ongoing Support

Suppliers regularly issue:

The Validation Plan should describe how these releases will be:

This ensures that supplier changes do not compromise the validated state.

Communication and Governance

Effective supplier involvement depends upon clear communication throughout the lifecycle of the computerised system.

The Validation Plan should define:

Clearly defined governance enables timely assessment of supplier activities and supports effective lifecycle management.

Inspection Perspective

Regulatory inspectors generally recognise that Commercial Off-the-Shelf software is developed and maintained by external suppliers.

Inspection activities therefore focus on whether the regulated organisation can demonstrate:

A well-defined supplier management strategy demonstrates that external activities remain subject to appropriate organisational governance.

Scientific Foundation

Supplier involvement is an integral component of modern Computerised System Validation. By qualifying suppliers, defining responsibilities, evaluating supplier documentation and maintaining effective oversight throughout the system lifecycle, organisations can leverage supplier expertise while retaining responsibility for demonstrating that pharmacovigilance computerised systems remain fit for their intended use.

Validation Lifecycle Management

Computerised System Validation does not conclude when a system is released into production. Instead, production deployment marks the beginning of a new lifecycle phase during which the validated state must be maintained despite software updates, business changes, regulatory developments and evolving operational requirements.

The Computerised System Validation Plan should therefore describe not only how validation will be established but also how it will be maintained throughout the operational life of the computerised system.

Lifecycle management provides confidence that the system continues to satisfy its intended use long after the original implementation project has been completed.

Maintaining the Validated State

The principal objective of lifecycle management is maintaining the validated state.

Maintaining the validated state means ensuring that the computerised system continues to:

This objective should guide every lifecycle activity performed after production deployment.

Change Control

Every proposed change should be evaluated before implementation.

Examples include:

The Validation Plan should describe how each change will undergo:

Effective change control is essential for preserving confidence in the validated state.

Regression Testing

Approved changes frequently require regression testing.

Regression testing should demonstrate that previously validated functionality continues to operate correctly following implementation of a change.

The Validation Plan should explain how organisations will determine:

Regression testing should be proportionate to the significance of the change and the associated risks.

Periodic Review

Validation should be reviewed at planned intervals throughout the operational lifecycle.

Periodic review commonly evaluates:

Periodic review provides documented assurance that the validated state has been maintained over time.

Incident and Problem Management

Operational incidents provide valuable information regarding the ongoing performance of the computerised system.

The Validation Plan should describe how incidents will be:

Where incidents identify weaknesses affecting validation assumptions, additional validation activities or system improvements may be required.

Corrective and Preventive Actions

Corrective and Preventive Actions (CAPAs) contribute to continual improvement of validated systems.

CAPAs may result from:

The Validation Plan should explain how CAPAs are incorporated into change control and validation activities while preserving traceability throughout the lifecycle.

Supplier Lifecycle Management

Supplier oversight continues after implementation.

The Validation Plan should describe how supplier activities such as:

will be reviewed and incorporated into the organisation's lifecycle management processes.

This ensures that supplier activities remain compatible with maintenance of the validated state.

Documentation Maintenance

Validation documentation should remain current throughout the lifecycle.

Documents requiring periodic review may include:

Maintaining current documentation improves governance and supports inspection readiness.

Retirement Planning

Validation responsibilities continue until the computerised system is formally retired.

The Validation Plan should describe how retirement activities will address:

Retirement planning demonstrates that lifecycle management extends beyond routine operational use.

Lifecycle Management Supports Continuous Compliance

Experienced organisations recognise that validation is maintained through disciplined lifecycle management rather than repeated validation projects.

By integrating change control, regression testing, supplier oversight, periodic review, incident management and documentation maintenance into routine governance processes, organisations ensure that pharmacovigilance computerised systems continue to operate in a controlled, validated and inspection-ready state throughout their operational lifecycle.

Scientific Foundation

Validation lifecycle management provides the governance framework through which organisations preserve the validated state of pharmacovigilance computerised systems after production deployment. By integrating change control, risk management, regression testing, periodic review, supplier oversight and continuous improvement, organisations maintain objective evidence that computerised systems remain fit for their intended use throughout their operational life.

Inspection Perspective

During regulatory inspections, the Computerised System Validation Plan is frequently one of the first validation documents requested. It provides inspectors with an overview of the organisation's validation strategy, governance framework and lifecycle management approach before they examine detailed validation evidence.

Inspectors rarely assess the Validation Plan in isolation. Instead, they evaluate whether subsequent validation activities have been performed consistently with the strategy described within the plan.

Accordingly, the Validation Plan should accurately represent how validation is actually performed rather than describing an idealised process that differs from operational practice.

Understanding the Validation Strategy

Inspectors commonly begin by determining whether the organisation has established a clear and scientifically justified validation strategy.

Typical areas of interest include:

The Validation Plan should enable inspectors to understand these principles without requiring extensive explanation.

Reviewing Governance

Validation requires effective governance throughout the lifecycle of the computerised system.

Inspectors may review whether responsibilities for:

have been assigned appropriately and are supported by organisational procedures.

Clearly documented governance demonstrates accountability and promotes confidence in the validation programme.

Assessing Risk-Based Validation

Modern regulatory expectations emphasise quality risk management rather than uniform validation of every system function.

Inspectors frequently evaluate whether the Validation Plan explains:

Organisations should therefore be prepared to justify validation decisions using documented risk assessments.

Confirming Consistency Between Documents

Inspectors commonly compare the Validation Plan with other validation deliverables.

Examples include:

Consistency across these documents demonstrates that the validation programme has been executed according to the approved strategy.

Reviewing Lifecycle Management

Validation extends beyond production deployment.

Inspectors frequently assess whether the Validation Plan adequately describes:

Evidence that these activities are routinely performed provides confidence that the validated state has been maintained.

Supplier Oversight

Where Commercial Off-the-Shelf or Software-as-a-Service solutions are used, inspectors generally expect organisations to demonstrate effective supplier oversight.

Typical areas of review include:

The Validation Plan should clearly distinguish supplier responsibilities from those retained by the regulated organisation.

Characteristics of an Effective Validation Plan

An inspection-ready Validation Plan is:

Inspectors generally place greater confidence in validation programmes where the documented strategy is reflected consistently throughout validation activities and operational practice.

What Inspectors Ultimately Evaluate

The principal question during inspection is not whether a Validation Plan exists.

Rather, inspectors seek evidence that the organisation has established and maintained a structured validation programme capable of ensuring that the pharmacovigilance computerised system remains fit for its intended use throughout its operational lifecycle.

A well-developed Validation Plan provides the framework through which this confidence can be demonstrated.

Inspection Insight

An effective Computerised System Validation Plan demonstrates far more than project planning. It provides inspectors with evidence that validation activities are governed by a consistent strategy, supported by quality risk management and maintained throughout the operational lifecycle of the pharmacovigilance computerised system. When the Validation Plan accurately reflects organisational practice, inspection readiness becomes a natural consequence of effective lifecycle governance.

How an Experienced CSV Lead Thinks About Validation Planning

Experienced Computerised System Validation professionals rarely view the Validation Plan as an administrative document prepared at the beginning of a project. Instead, they regard it as the governance framework that defines how confidence in the validated state will be established and maintained throughout the operational life of the computerised system.

Their objective is not to produce documentation. Their objective is to establish a validation programme that consistently generates objective evidence demonstrating that the system remains fit for its intended use.

For experienced validation professionals, the Validation Plan is therefore the blueprint for lifecycle governance rather than a project deliverable.

They Begin With the Business

Experienced CSV Leads rarely begin by discussing software.

Instead, they begin by asking:

Only after understanding these questions do they begin planning validation activities.

Validation therefore starts with business objectives rather than technology.

They Think in Terms of Intended Use

Experienced professionals recognise that intended use is the organising principle for the entire validation programme.

They understand that:

should all demonstrate confidence that the intended use continues to be achieved.

Whenever validation decisions become uncertain, they return to the intended use as the primary reference point.

They Think About Risk Before Documentation

Experienced CSV Leads do not begin by asking which templates must be completed.

Instead, they ask:

Only after understanding these risks do they determine the appropriate validation strategy.

Consequently, documentation reflects scientific judgement rather than administrative convention.

They View Validation as a Lifecycle Process

Experienced professionals recognise that implementation represents only one stage within the lifecycle of a computerised system.

When preparing the Validation Plan they consider:

They therefore create validation programmes capable of supporting the organisation for many years rather than only supporting initial deployment.

They Integrate Governance

Experienced validation professionals understand that successful validation depends upon governance rather than documentation alone.

Accordingly, they ensure that responsibilities for:

are clearly defined before validation begins.

Strong governance reduces uncertainty throughout the lifecycle.

They Generate Confidence Rather Than Paperwork

Experienced CSV Leads rarely measure success by:

Instead, they ask:

Their focus remains on generating meaningful assurance rather than documentation volume.

They Think About the Next Inspection Every Day

Inspection readiness is not viewed as a separate activity.

Experienced professionals assume that validation documentation should be inspection-ready throughout the lifecycle.

They routinely ask:

Maintaining this discipline reduces the effort required to prepare for regulatory inspections.

They Build Validation Programmes That Can Evolve

Experienced CSV Leads recognise that no validation programme remains static.

Accordingly, they design Validation Plans that accommodate:

A Validation Plan should therefore support adaptation without compromising control.

They Measure Success by Confidence

Ultimately, experienced validation professionals judge a Validation Plan by one question:

"Does this Validation Plan provide a clear, risk-based and scientifically justified framework that enables the organisation to demonstrate that the pharmacovigilance computerised system remains fit for its intended use throughout its lifecycle?"

If the answer is yes, the Validation Plan has fulfilled its purpose.

Professional Reflection

Experienced Computerised System Validation professionals recognise that a Validation Plan is fundamentally a governance document. It integrates intended use, quality risk management, lifecycle thinking, objective evidence and organisational accountability into a single strategy that guides every validation activity. The quality of the Validation Plan is reflected not by the volume of documentation it generates, but by the confidence it provides that the validated state can be established, maintained and defended throughout the operational life of the pharmacovigilance computerised system.

Key Takeaways

A Computerised System Validation Plan defines the strategy through which an organisation establishes and maintains confidence that a pharmacovigilance computerised system is fit for its intended use. It describes the intended use, validation scope, governance arrangements, quality risk management approach, validation activities, supplier involvement and lifecycle management processes that guide the validation programme.

Rather than functioning as a project document alone, the Validation Plan serves as the governance framework for the complete lifecycle of the computerised system. By integrating risk-based validation, objective evidence, effective supplier oversight, change control and periodic review, organisations can maintain the validated state while supporting patient safety, data integrity and regulatory compliance throughout the operational life of the system.

Related Articles

Traceability Matrix in Computerised System Validation

Learn how traceability matrices connect business requirements, risk assessments, specifications, validation testing and objective evidence throughout the lifecycle of validated pharmacovigilance systems.

Validation Testing in Pharmacovigilance: IQ, OQ, PQ and User Acceptance Testing

Learn how validation testing provides objective evidence that pharmacovigilance computerised systems are fit for their intended use through risk-based qualification and testing strategies.

Functional Specifications and Design Specifications in Pharmacovigilance

Learn how business requirements defined in the User Requirements Specification are translated into functional and technical system designs while supporting risk-based validation and regulatory compliance.

Last reviewed: 2026-07-12